AbbVie Inc. closed 15.13% below its 52-week high of $218.66, which the company reached on March 10th.

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top ...

AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, indicating ...

AbbVie Inc. ABBV, a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company's stock traded at ...

Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns President Donald Trump signed an executive order Monday directing ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 93% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie Inc. closed 10.33% short of its 52-week high of $218.66, which the company reached on March 10th.

It beat the consensus estimate in each of the last four quarters. Among the 26 analysts covering ABBV stock, the consensus is a “Moderate Buy.” That’s based on 15 “Strong Buy” ratings ...